

Section 30<h2>

Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic Myelomonocytic Leukemia (CMML)

This section includes Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic Myelomonocytic Leukemia (CMML). In the 3rd edition of the International Classification of Diseases for Oncology, the behavior code of myelodysplastic syndromes and chronic myeloproliferative disorders was changed from /1, borderline malignancy or low malignant potential, to /3, malignant primary site. These diagnoses became reportable for cases diagnosed in 2001+ when ICD-O-3 went into effect. CMML has been reportable for all years. CMML is included here and in the leukemia section.

Table 30.1

Myelodysplastic Syndromes, Chronic Myeloproliferative Disorders, and Chronic Myelomonocytic Leukemia

Counts, Percents and Age-Adjusted Incidence Rates^a for the 17 SEER Geographic Areas by Subtype, 2002-2006

Site	Both Sexes			Males			Females		
	Count	Percent	Rate	Count	Percent	Rate	Count	Percent	Rate
Total	24,020	100.0%	6.7	13,052	100.0%	8.7	10,968	100.0%	5.3
Myelodysplastic Syndromes (MDS)	14,324	100.0%	4.0	7,863	100.0%	5.4	6,461	100.0%	3.1
Refractory anemia (RA), NOS	2,094	14.6%	0.6	1,084	13.8%	0.7	1,010	15.6%	0.5
RA with ringed sideroblasts	1,432	10.0%	0.4	807	10.3%	0.6	625	9.7%	0.3
RA with excess blasts (RAEB)	1,988	13.9%	0.6	1,198	15.2%	0.8	790	12.2%	0.4
RAEB in transformation	138	1.0%	0.0	71	0.9%	0.0	67	1.0%	0.0
Refractory cytopenia w/multilineage dysplasia	724	5.1%	0.2	458	5.8%	0.3	266	4.1%	0.1
Myelodysplastic syndrome with 5q deletion	241	1.7%	0.1	92	1.2%	0.1	149	2.3%	0.1
Therapy-related myelodysplastic syndrome	237	1.7%	0.1	105	1.3%	0.1	132	2.0%	0.1
Myelodysplastic syndrome, NOS	7,470	52.2%	2.1	4,048	51.5%	2.8	3,422	53.0%	1.6
Chronic Myeloproliferative Disorders (CMD)	8,370	100.0%	2.3	4,388	100.0%	2.7	3,982	100.0%	2.0
Polycythemia vera	3,481	41.6%	0.9	2,030	46.3%	1.2	1,451	36.4%	0.7
Chronic myeloproliferative disease, NOS	1,502	17.9%	0.4	783	17.8%	0.5	719	18.1%	0.4
Myelosclerosis with myeloid metaplasia	894	10.7%	0.2	523	11.9%	0.3	371	9.3%	0.2
Essential thrombocythemia	2,322	27.7%	0.6	956	21.8%	0.6	1,366	34.3%	0.7
Chronic neutrophilic leukemia	21	0.3%	0.0	-	-	-	-	-	-
Hypereosinophilic syndrome	150	1.8%	0.0	84	1.9%	0.0	66	1.7%	0.0
Chronic Myelomonocytic Leukemia (CMML)	1,326	100.0%	0.4	801	100.0%	0.6	525	100.0%	0.3

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- Statistic not shown due to fewer than 16 cases during the time period.

Table 30.2

Myelodysplastic Syndromes, Chronic Myeloproliferative Disorders, and
Chronic Myelomonocytic Leukemia

Age-Adjusted Incidence Rates^a for the 17 SEER Geographic Areas by Age and Race, 2002-2006

Site	Both Sexes		Males		Females	
	Rate	Count	Rate	Count	Rate	Count
Myelodysplastic Syndromes (MDS)						
By age						
Ages <40	0.2	354	0.2	189	0.2	165
Ages 40-49	0.8	463	0.8	221	0.8	242
Ages 50-59	2.3	1,069	2.6	582	2.1	487
Ages 60-69	8.5	2,253	9.8	1,228	7.3	1,025
Ages 70-79	24.8	4,718	33.9	2,770	17.9	1,948
Ages 80+	43.9	5,467	65.6	2,873	32.2	2,594
By race						
All Races	4.0	14,324	5.4	7,863	3.1	6,461
White	4.1	12,204	5.6	6,799	3.1	5,405
Black	3.6	1,023	4.3	477	3.2	546
Asian/Pacific Islander	2.9	813	3.7	436	2.3	377
American Indian/Alaska Native ^b	2.3	41	2.6	20	2.3	21
Hispanic ^c	3.0	1,062	3.7	556	2.5	506
Chronic Myeloproliferative Disorders (CMD)						
By age						
Ages <40	0.3	596	0.3	336	0.2	260
Ages 40-49	1.4	848	1.6	480	1.2	368
Ages 50-59	2.9	1,326	3.6	799	2.2	527
Ages 60-69	6.3	1,690	7.5	949	5.2	741
Ages 70-79	11.6	2,197	13.7	1,123	9.9	1,074
Ages 80+	13.8	1,713	15.9	701	12.6	1,012
By race						
All Races	2.3	8,370	2.7	4,388	2.0	3,982
White	2.3	6,861	2.7	3,647	1.9	3,214
Black	2.2	709	2.6	351	2.0	358
Asian/Pacific Islander	1.7	532	1.8	260	1.6	272
American Indian/Alaska Native ^b	1.0	21	-	-	-	-
Hispanic ^c	1.5	663	1.8	352	1.3	311
Chronic Myelomonocytic Leukemia (CMML)						
By age						
Ages <40	0.0	21	-	-	-	-
Ages 40-49	0.0	16	-	-	-	-
Ages 50-59	0.2	81	0.2	43	0.2	38
Ages 60-69	0.8	221	1.2	154	0.5	67
Ages 70-79	2.6	491	3.9	322	1.6	169
Ages 80+	4.0	496	5.9	263	2.9	233
By race						
All Races	0.4	1,326	0.6	801	0.3	525
White	0.4	1,183	0.6	713	0.3	470
Black	0.3	69	0.4	39	0.2	30
Asian/Pacific Islander	0.2	62	0.4	43	0.1	19
American Indian/Alaska Native ^b	-	-	-	-	-	-
Hispanic ^c	0.3	90	0.4	59	0.2	31

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanics are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic not shown due to fewer than 16 cases during the time period.